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Introduction {#sec005}
============

Diabetes is a rising social and epidemiological issue. Patients with type 2 diabetes mellitus (T2DM) are at risk of frequent complications, included cardiovascular, renal, neural, and retinal diseases. In addition, T2DM has significant morbidity and mortality across the world \[[@pone.0237109.ref001]\]. For instance, population-based studies have reported that majority of T2DM patients develop diabetic peripheral neuropathy (DPN), and close to 30% of these patients have clinical manifestations \[[@pone.0237109.ref002], [@pone.0237109.ref003]\]. Importantly, up to 50% of patients with DPN are asymptomatic \[[@pone.0237109.ref004]\]. Exact factors contributing to development of T2DM are unclear, but it seems that diabetes has more diverse etiology, than previously thought.

The studies conducted in type 1 diabetes mellitus (T1DM) patients with severe autonomic neuropathy have documented that lymphocytic infiltration and small nerve fiber damage in autonomic ganglia indicates a vigorous immune response \[[@pone.0237109.ref005]\]. Circulating auto-antibodies in sera of patients with T1DM have been reported that make a reaction with autonomic conditions, such as sympathetic ganglia and vagus nerve. This reaction might be associated with the future development of autonomic neuropathy \[[@pone.0237109.ref006]\].

About DPN, Granberg, Ejskjaer \[[@pone.0237109.ref006]\] mentioned that it is unclear whether autoimmunity has a primary role in the disease pathogenesis, or it escalates the DPN initiation by metabolic or vascular injury.

The anti-GAD65 (glutamic acid decarboxylase) antibody is a strong predictive marker for the onset of T1DM \[[@pone.0237109.ref007]\]. The presence of this antibody in patients with recent-onset T1DM was associated with hyperglycemia and reduced peripheral nerve function, suggesting a common mechanism for β-cell and neuronal damage \[[@pone.0237109.ref008]\]. Decreased motor nerve conduction velocities in the median, ulnar and peroneal nerves were observed in patients who have high GAD65 antibodies along with prolonged F wave latencies, high thermal threshold detection for hot and cold, and decreased cardiovascular autonomic functions \[[@pone.0237109.ref008]\].

A study conducted by Srinivasan, Stevens \[[@pone.0237109.ref009]\] demonstrated that serum of T2DM patients with neuropathy contains an autoimmune immunoglobulin that induces independent complement and calcium-dependent apoptosis in neuronal cells. An intense fluorescence on the surface of neuronal cells has been shown to relate to anti-human IgG antibody in neuropathic T2DM patients \[[@pone.0237109.ref009]\]. Some other inflammatory biomarkers have been seen in patients with coronary artery diseases (CAD) \[[@pone.0237109.ref006]\]. Unsuitable inflammatory responses maybe related to both increased chronic development of atherosclerotic plaques and an increased plague rupture associated with acute myocardial infarction \[[@pone.0237109.ref010]\].

Although different studies suggested that antibodies may be present in the sera of T2DM patients with complications, the development of complications in these patients needs further investigation. There is no definitive report of the prevalence of a systemic immune reaction, characterized by the presence of high titers of antinuclear antibodies (ANA) in T2DM patients with chronic microvascular complications yet \[[@pone.0237109.ref011]--[@pone.0237109.ref013]\].

The rate of autoimmune diseases in the general population is rising more than it previously reported in the literature \[[@pone.0237109.ref014], [@pone.0237109.ref015]\]. In addition, it has been reported that patients with T2DM have more occurrence of autoimmune diseases that it was previously reported \[[@pone.0237109.ref001]\]. An increased destruction of cells in various organs following microangiopathy and macroangiopathy may induce a secondary immune response. This response may aggravate further course of chronic complications. Anti-nuclear antibodies (ANA) could be a biomarker or be directly involved in chronic complications of diabetes since it is produced in response to cell necrosis or cell apoptosis. Therefore, this kind of relation may be a notion for the higher prevalence of antinuclear antibodies in more severe forms of coronary atherosclerosis \[[@pone.0237109.ref001]\].

The role of reaction to ANA in T2DM patients with complications has been investigated in a few studies, mostly by a qualitative and in a few investigations by a semi-quantitative method. Given to controversy findings on the role of ANA in the development of the complications in T2DM \[[@pone.0237109.ref011], [@pone.0237109.ref012]\]. But, the development of micro-complications in patients with T2DM could be searched in an anti- nucleolus level rather than nuclear one. Human Anti Nucleolus Antibody (ANCAb) may have a role in the development of complications. With the currently available hints on the possible role of ANA in the development or escalation of T2DM, it is so valuable to examine this role in a sample of complicated and non-complicated patients. The prevalence of reaction to ANCAb was compared between a sample of patients with T2DM and complications and a sample of T2DM without complications. The investigators anticipated the higher prevalence of reaction to ANCAb in T2DM patients with complications compared to those patients without complications.

Patients and methods {#sec006}
====================

Study design and sampling {#sec007}
-------------------------

The patients who were diagnosed with T2DM by the study internist were screened physically and clinically for the eligibility criteria of the study. In the current case-control study, 38 patients with T2DM (41--64 years old) affected by various complications, including neuropathy, retinopathy, cardiovascular, or nephropathy were included and their biochemical parameters and ANCAb reaction were compared with 43 non-complicated patients with T2DM (37--64 years old). The T2DM patients in both study groups were matched in age (P = 0.115) and gender (P = 0.244) prior to study analysis. The complicated patients with neuropathy, retinopathy, cardiovascular, or nephropathy were considered exposed/case group. The patients who attended the out-patient clinic for medical check-up or receiving their regular medications were screened physically and clinically by the study internist. The study internist has weekly regular clinical duty in the out-patient clinic. The patients were screened for the possible complications of T2DM and consisted microvascular diseases, neuropathy, nephropathy, and retinopathy. The patients who were diagnosed to have one of the mentioned above complications following diabetes were categorized as T2DM patients with complication. The T2DM patients who did not have the complications were categorized as T2DM patients without complications.

The patients were recruited purposively from Duhok Diabetes Center of Azadi Teaching Hospital following taking ethical approval from the local department, and written consent forms from patients. The data collection was performed between 3^rd^ November 2018 and 24^th^ February 2019.

The patients who attended the center for medical check-up or treatment were screened consecutively for the inclusion criteria. The internist of the study (fifth author) performed physical and clinical examinations for all patients for medical conditions and diabetes complications before inclusion in the study.

Inclusion and exclusion criteria {#sec008}
--------------------------------

The patients who were diagnosed with T2DM with and without microvascular complications aged 35 years and older of both gender and have diabetes since the last five years regardless of their socio-demographic aspects were eligible to be recruited in this study. Those with autoimmune disease including either organ-specific illnesses (e.g., thyroid disease, type 1 diabetes mellitus (T1DM), and myasthenia gravis) or systemic diseases (e.g., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and pregnant patients, active infection or inflammation, and the patients on hormone replacement therapy were excluded through the clinical examination and self-reported technique.

The patients who were included in this study were previously diagnosed with T2DM. The patients were consecutively screened through physical and clinical examinations and history taking for eligibility criteria. The information such as age, gender, disease duration, and anthropometric measures were recorded in a pre-designed questionnaire. The treatments of the patients were checked by the study internist. The internist asked the patients about the history of disease and its complications to be sure that the current complications belong to the disease. To include the suitable sample in the study, the patients were screened for the disease comorbidities.

Diagnosis and measurement criteria {#sec009}
----------------------------------

The diagnosis of T2DM was established in accordance with the criteria of the World Health Organization \[[@pone.0237109.ref016]\]. The diagnosis of the medical conditions was established through the medical and clinical examinations by the study internist. In this investigation, cardiovascular disease was defined as a class of diseases affecting the heart and blood vessels, as explained by the WHO \[[@pone.0237109.ref017]\]. The patients who had the following 12 cardiovascular presentations following diabetes development were considered the cases with CVD complications. The CVD conditions were: stable angina, unstable angina, heart failure, unheralded coronary death, myocardial infarction, ischemic stroke, transient ischemic attack, peripheral arterial disease, subarachnoid hemorrhage, intracerebral hemorrhage, abdominal aortic aneurysm and a composite outcome consisted of cardioversion, ventricular arrhythmia, implantable cardioverter defibrillator, and cardiac arrest \[[@pone.0237109.ref018]\]. The HbA1C \<7% was considered controlled diabetes and ≥7% as uncontrolled diabetes \[[@pone.0237109.ref019]\].

Diabetic peripheral neuropathy (DPN) diagnosis {#sec010}
----------------------------------------------

Polyneuropathy-neurological examination was performed for superficial sensation, by indicators such as pain, touch, and temperature. Also, the following tests were performed: vibration perception with tuning fork and monofilament test. The neuropathy was diagnosed in accordance with the criteria of the American Academy of Neurology (AAN) through a combination of neuropathic symptoms, multiple signs, and abnormal electro-diagnostic studies \[[@pone.0237109.ref020]\].

Nephropathy {#sec011}
-----------

The diabetic nephropathy was diagnosed according to the clinical examination and biochemical parameters by the study internist \[[@pone.0237109.ref021]\]. The albumin was measured in a spot urine sample as the first step in the screening and diagnosis of diabetic nephropathy during medical visit as recommended by American Diabetes Association guidelines \[[@pone.0237109.ref022]\]. The following albuminuria cutoff were considered for microalbuminuria and macro-albuminuria stages \[[@pone.0237109.ref023]\].

Retinopathy {#sec012}
-----------

The patients who had a complaint on their visions were referred to an ophthalmologist for the vision tests for the disease confirmation. The patients who had the following symptoms were screened for diabetic retinopathy. The symptoms for the diagnosis of diabetic retinopathy were finding spots or floaters, blurred vision, having a dark or empty spot in the center of your vision, and difficulty seeing well at night. Accordingly, the diagnostic clinical manifestations were leaking blood vessels, swelling inside the retina, pale, fatty deposits on the retina, damaged nerve tissue, and any changes to the blood vessels \[[@pone.0237109.ref024]\].

Biochemical measurements {#sec013}
------------------------

The investigators collected 10 ml of the venous blood samples from all patients following overnight fasting (= \>12 hrs.) by an experienced phlebotomist. The obtained samples were centrifuged at 3,000 rpm at 4°C for 15 min. Their supernatants were decanted and frozen at -30°C and assayed. The biochemical measurements were determined using Roche autoanalyzer 6000 Cobas (Roche Diagnostics, Mannheim, Germany) in the medical lab of the hospital. In this study, the biochemical measurements were calculated from the serum samples. The biochemical parameters, including, lipid profile, liver function tests, renal function tests, insulin, and HbA1C, were measured through the biochemical techniques. The biochemical measurements were performed in the medical lab of Azadi Teaching Hospital in Duhok city.

Anthropometric measurements {#sec014}
---------------------------

The patients' weight was measured in Kg scaled by Bathroom Scale, a digital scale nearest to 0.1 cm. Waist circumference (WC) was measured in the horizontal plane by non-stretch tape in the midway place between the lateral lower ribs and the iliac crests by Double-Scale Soft Tape with the nearest 0.1 cm. Recommended cut-offs for increased health risk are a waist circumference of more than 102 cm for men and more than 88 cm for women \[[@pone.0237109.ref025]\].

Human anti nucleolus antibody measurement {#sec015}
-----------------------------------------

The measurement of serum ANCAb was performed using Human Anti Nucleolus Antibody (ANCA, (Competitive ELISA Kit), Catalog Number: MBS7228076--96 tests from MyBioSource, Inc. The USA. ELx800 Universal Microplate Reader with ELx50 Auto Strip Washer was used for ANCAb measurement. This ANCAb ELISA kit is a 1.5-hour solid-phase ELISA designed for the quantitative determination of Human ANCAb. The concentration of antibody was determined by comparison to a standard curve generated by known concentrations of ANCAb ranged 0--100 ng/mL \[[@pone.0237109.ref026]\].

In the current study, any reaction of ANCAb with components of the body\'s healthy cells was considered a reacted ANCAb. ANCAb specifically target substances originated in the nucleolus of a cell, hence the name \"antinucleoli\" They probably do not damage living cells because they cannot access their nucleoli. However, ANCAb can cause damage to tissue by reacting with nuclear substances when they are released from injured or dying cells \[[@pone.0237109.ref026]\].

ANCAb ELISA kit applies the competitive enzyme immunoassay technique. This technique utilizes Nucleolus antigen and an ANCAb-HRP conjugate. The assay sample and buffer were incubated together with ANCAb-HRP conjugate in pre-coated plate for one hour. Following the incubation period, the wells were decanted and washed five times and the wells were incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction was a blue colored complex. Finally, a stop solution was added to stop the reaction. Subsequently, the color turned to the yellow. The color intensity was measured spectrophotometrically at 450 nm in a microplate reader. The intensity of the color was inversely proportional to the ANCAb concentration, because ANCAb from samples and ANCAb-HRP conjugate compete for the Nucleolus antigen binding site. Since the number of sites is limited, as more sites are occupied by ANCAb from the sample, fewer sites were left to bind ANCAb-HRP conjugate. A standard curve was plotted relating the intensity of the color (O.D.) to the concentration of standards. The ANCAb concentration in each sample was interpolated from this standard curve.

The sensitivity of this assay was 1.0 ng/mL. This assay has high sensitivity and excellent specificity to detect ANCAb. There is no significant cross-reactivity or interference between ANCAb and analogues. **NOTE**: The catalogue mentioned that the assay is limited by current skills and knowledge. It added that it was impossible to complete the cross-reactivity detection between ANCAb and all the analogues, therefore, cross reaction may still exist in some cases.

Statistical analysis {#sec016}
--------------------

The normality of the biochemical and general parameters between the patients in both complicated and non-complicated patients was tested through drawing a histogram between two groups. The outliers of the biochemical parameters in both study groups were examined and deleted by a Box-Plots. The frequency percentage and mean standard deviation was performed for descriptive purposes of the study. The comparison of general characteristics between the patients in both study groups was examined in an independent t-test, Pearson Chi-square test, Fishers' exact test, or Mann-Whitney U-test.

The comparison of biochemical indicators between the patients in complicated and non-complicated groups was examined in an independent t-test. The difference in the prevalence of ANCAb reaction between the complicated and non-complicated patients was examined in Pearson chi-squared or Fishers' exact tests. The level of ANCAb was transformed trough SQRT method, and the comparison of the median values of the complicated and non-complicated was examined in Mann-Whitney U-test. The magnitude of the association was calculated in an odds ratio. The level of less than 0.05 was considered the statically significant difference. The SPSS version 24 is used for the statistical calculations.

Ethical approval {#sec017}
----------------

The ethical approval of the present investigation was obtained from the Scientific Research Division, Directorate of Planning, Duhok Directorate General of Health, registered as reference number 17042018--3 on 28^th^ October 2018 in accordance with the principles of the Declaration of Helsinki \[[@pone.0237109.ref027]\].

Results {#sec018}
=======

The study revealed that the patients with and without diabetic complication were comparable in age (53.34 vs. 50.90 years, P = 0.115), and diabetes duration (9.0 vs. 5.0 years; P = 0.065), number of patients with high school certificate and higher (5.3% vs. 11.6%; P = 0.439), smokers (13.2% vs. 14.0%; P = 0.917), and gender (Male: 31.6% vs. 44.2%; P = 0.244), respectively. The patients in both with and without diabetic complication were similar in BMI (27.92 vs. 29.26; P = 0.175), while the patients without diabetic complication had a greater waist circumference (107.95 cm) compared to patients with diabetic complication (102.30 cm; P = 0.021), as presented in [Table 1](#pone.0237109.t001){ref-type="table"}.

10.1371/journal.pone.0237109.t001

###### Comparison of general information between type 2 diabetes mellitus with and without complications.

![](pone.0237109.t001){#pone.0237109.t001g}

  Patients' characteristics                                                    Patient with diabetic complication (n = 38)   Patient without diabetic complication (n = 43)   P-Value (two-sided)
  ---------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------ ---------------------------------------------
  **Age** (year)                                                               53.34 (6.94)                                  50.93 (6.63)                                     0.115[^a^](#t001fn002){ref-type="table-fn"}
  **Range**: 37--64 years                                                      41--64                                        37--64                                           
  **Waist Circumference (cm) Range**: 80--126 cm                               102.30 (11.97) 80--125                        107.95 (8.65) 92--126                            0.021[^a^](#t001fn002){ref-type="table-fn"}
  **WC Categories**                                                                                                                                                           0.275[^b^](#t001fn003){ref-type="table-fn"}
      Healthy                                                                  13 (34.2)                                     10 (23.3)                                        
      Unhealthy                                                                25 (65.8)                                     33 (76.7)                                        
      **Diabetes duration;** Median/Interquartile Range Range: 0.5--30 years   9.0 (6.0)                                     5.0 (7.0)                                        0.065[^d^](#t001fn005){ref-type="table-fn"}
  **BMI**                                                                      27.92 (4.45)                                  29.26 (3.91)                                     0.175[^a^](#t001fn002){ref-type="table-fn"}
  Range: 17.58--38.31                                                          17.58--34.79                                  20.14--38.31                                     
  **Education Categories**                                                                                                                                                    0.439[^c^](#t001fn004){ref-type="table-fn"}
      Under High School                                                        36 (94.7)                                     38 (88.4)                                        
      High School and Higher                                                   2 (5.3)                                       5 (11.6)                                         
  Smokers                                                                      5 (13.2)                                      6 (14.0)                                         0.917[^b^](#t001fn003){ref-type="table-fn"}
  **Gender**                                                                                                                                                                  0.244[^b^](#t001fn003){ref-type="table-fn"}
      Male                                                                     12 (31.6)                                     19 (44.2)                                        
      Female                                                                   26 (68.4)                                     24 (55.8)                                        

The following statistical tests were performed:

^a^Independent t-test

^b^Pearson Chi-square test

^c^Fishers' exact test

^d^Mann-Whitney U-test

The study showed that the patients with and without complication were comparable in most biochemical parameters (P\>0.05). However, patients with diabetic complication had a lower concentration of creatinine (0.68 vs. 0.77 mg/dL; P = 0.041) and urea (27.78 vs. 33.12 mg/dL; P = 0.013), respectively compared to the patients without diabetic complication ([Table 2](#pone.0237109.t002){ref-type="table"}).

10.1371/journal.pone.0237109.t002

###### Comparison of biochemical parameters between type 2 diabetic patients with and without complications.

![](pone.0237109.t002){#pone.0237109.t002g}

  Biochemical Parameters      Study Groups                      
  --------------------------- ---------------- ---------------- --------------------------------------------------
  Total cholesterol; mg/dL    188.89 (41.88)   189.19 (41.20)   0.975[^a^](#t002fn001){ref-type="table-fn"}
  HDL; mg/dL                  44.89 (11.02)    40.40 (9.26)     0.051 [^a^](#t002fn001){ref-type="table-fn"}
  LDL; mg/dL                  105.86 (34.03)   112.39 (30.82)   0.387 [^a^](#t002fn001){ref-type="table-fn"}
  T.G; mg/dL                  157.21 (56.21)   171.67 (66.09)   0.319 [^a^](#t002fn001){ref-type="table-fn"}
  Albumin; g/dL               4.43 (0.31)      4.54 (0.29)      0.121 [^a^](#t002fn001){ref-type="table-fn"}
  Urea; mg/dL                 27.78 (8.13)     33.12 (10.59)    **0.013** [^a^](#t002fn001){ref-type="table-fn"}
  Creatinine; mg/dL           0.68 (0.18)      0.77 (0.20)      **0.041** [^a^](#t002fn001){ref-type="table-fn"}
  U.A; mg/dL                  4.55 (1.34)      4.50 (1.08)      0.838 [^a^](#t002fn001){ref-type="table-fn"}
  GOT; U/L                    16.11 (4.82)     17.88 (4.07)     0.089 [^a^](#t002fn001){ref-type="table-fn"}
  GPT; U/L                    19.84 (6.38)     22.37 (8.43)     0.136 [^a^](#t002fn001){ref-type="table-fn"}
  Alkaline Phosphatase; U/L   96.21 (29.67)    105.84 (37.29)   0.211 [^a^](#t002fn001){ref-type="table-fn"}
  HbA1C; %                    8.30 (1.96)      7.79 (1.19)      0.171 [^a^](#t002fn001){ref-type="table-fn"}
  **Range**: 4.60--13.20      4.60--13.20      5.90--10.0       
  **HbA1C Categories**                                          0.696[^b^](#t002fn002){ref-type="table-fn"}
      Uncontrolled Diabetes   28 (73.7)        30 (69.8)        
      Controlled Diabetes     10 (26.3)        13 (30.2)        

^a^The independent t-test and

^b^ Pearson Chi-squared test were performed for statistical analyses.

The bold numbers show a significant difference.

The study showed that 27 cases (71.1%) in patients with diabetic complication reacted to the ANCAb test compared to 25 (58.1%) in patients without diabetic complication, while the overall difference of prevalence was not statistically significant (P = 0.226). The median values of the transformed ANCAb in both groups of patients with and without diabetic complication were 3.53 and 2.72 ng/mL, respectively with no statistically significant difference (P = 0.413), as presented in [Table 3](#pone.0237109.t003){ref-type="table"} and [Fig 1A](#pone.0237109.g001){ref-type="fig"}.

![a. Presentation of ANCAb concentration (transformed ANCAb) between patients with and without diabetic microvascular complications. b. Presentation of ANCAb (transformed ANCAb) among patients with uni and multi microvascular complications. c. Presentation of ANCAb (transformed ANCAb) among patients with different microvascular complications. d. Presentation of ANCAb (transformed ANCAb) among study groups based the HbA1C control.](pone.0237109.g001){#pone.0237109.g001}

10.1371/journal.pone.0237109.t003

###### Comparison of human anti-nucleolus antibody between type 2 diabetic patients with and without complications.

![](pone.0237109.t003){#pone.0237109.t003g}

  Human Anti Nucleolus Antibody (ANCAb)   Study Groups   OR (95% CI)   P-Value (two-sided)   
  --------------------------------------- -------------- ------------- --------------------- ---------------------------------------------
  **ANCAb reaction**                                                                         0.226[^a^](#t003fn001){ref-type="table-fn"}
      Reacted                             27 (71.1)      25 (58.1)     1.77 (0.7--4.46)      
      Non-reacted                         11 (28.9)      18 (41.9)                           
  **Males**                                                            1.80 (0.40--8.07)     0.440[^a^](#t003fn001){ref-type="table-fn"}
  **    Reacted**                         8 (66.7%)      10 (52.6%)                          
  **    Non-Reacted**                     4 (33.3%)      9 (47.4%)                           
  **Females**                                                          1.63 (0.49--5.39)     0.423[^a^](#t003fn001){ref-type="table-fn"}
  **    Reacted**                         19 (73.1%)     15 (62.5%)                          
  **    Non-Reacted**                     7 (26.9%)      9 (37.5%)                           
  ANCAb, ng/mL                            3.53 (4.91)    2.72 (4.83)                         0.413[^b^](#t003fn002){ref-type="table-fn"}
      Range: 0.0--10.87                   0.0--10.87     0.0--9.29                           
  **Males**                               3.37 (4.86)    2.54 (4.55)                         0.768
  **Females**                             3.88 (4.91)    2.75 (4.98)                         0.540

^a^Pearson Chi-squared and

^b^Mann Whitney U-test was performed for statistical analyses.

The study did not show the significant difference in the concentration of ANCAb between the patients who had controlled and uncontrolled T2DM in patients with and without diabetic complication ([Table 4](#pone.0237109.t004){ref-type="table"} & [Fig 1D](#pone.0237109.g001){ref-type="fig"}).

10.1371/journal.pone.0237109.t004

###### Comparison of ANCAb between controlled and uncontrolled diabetes in study groups.

![](pone.0237109.t004){#pone.0237109.t004g}

  Study Groups                            HbA1C Categories   P-Value (two-sided)   
  --------------------------------------- ------------------ --------------------- -------
  Patient with diabetic complication      3.53 (4.36)        3.67 (5.27)           0.893
  Patient without diabetic complication   3.11 (4.97)        2.67 (4.55)           0.690

Mann-Whitney U-test was performed for statistical analyses.

To have a better picture of the reaction to ANCAb in patients with different types of complications, the prevalence of ANCAb reaction in different categories of complications was presented in [Table 5](#pone.0237109.t005){ref-type="table"} & [Fig 1C](#pone.0237109.g001){ref-type="fig"}. The study revealed that the patients with neuropathy along with cardiovascular complications had a higher reaction response to ANCAb (80.0%) followed by those with neuropathy (76.2%) compared to 58.1% in the non-complicated group (P = 0.398). Similarly, the patients with mono-complication had a higher reaction response to ANCAb (72.7%) compared to those patients with multi-complication (68.8%), but the overall difference in prevalence was not statistically significant (P = 0.466), as presented in [Table 5](#pone.0237109.t005){ref-type="table"} & [Fig 1B](#pone.0237109.g001){ref-type="fig"}.

10.1371/journal.pone.0237109.t005

###### Association of ANCAb reaction to complications categories in patients with T2DM.

![](pone.0237109.t005){#pone.0237109.t005g}

  Compilations                                                       Total Complications   Reaction to ANCAb   P-Value (two-sided)               
  ------------------------------------------------------------------ --------------------- ------------------- --------------------- ----------- ---------------------------------------------
  **Complication Categories**                                                                                                                    0.170[^c^](#t005fn003){ref-type="table-fn"}
      Retinopathy                                                    1 (1.2)               0.0                 0 (0.0)               1 (100.0)   0.398[^b^](#t005fn002){ref-type="table-fn"}
      Neuropathy                                                     21 (25.9)             3.43 (2.69)         16 (76.2)             5 (23.8)    
      Retino-neuropathy                                              7 (8.6)               3.23 (2.66)         5 (71.4)              2 (28.6)    
      Neuro-CVD                                                      5 (6.2)               3.44 (2.03)         4 (80.0)              1 (20.0)    
      Neuro-Retino-Nephropathy                                       3 (3.7)               1.58 (2.74)         1 (33.3)              2 (66.7)    
      Neuro-Nephropathy                                              1 (1.2)               9.59                1 (100.0)             0 (0.0)     
      non-complicated                                                43 (53.1)             2.75 (2.69)         25 (58.1)             18 (41.9)   
  **Complication Numbers**                                                                                                                       0.643[^c^](#t005fn003){ref-type="table-fn"}
      Multi-complication                                             16 (19.8)             3.38 (2.86)         11 (68.8)             5 (31.3)    0.466[^a^](#t005fn001){ref-type="table-fn"}
      Mono-complication                                              22 (27.2)             3.27 (2.73)         16 (72.7)             6 (27.3)    
      Non-complicated                                                43 (53.1)             2.75 (2.69)         25 (58.1)             18 (41.9)   
  **Complication Categories[\^](#t005fn004){ref-type="table-fn"}**                                                                               0.350[^c^](#t005fn003){ref-type="table-fn"}
      Neuropathy                                                     21 (32.8)             3.43 (2.69)         16 (76.2)             5 (23.8)    0.158[^a^](#t005fn001){ref-type="table-fn"}
      non-complicated                                                43 (67.2)             2.75 (2.69)         25 (58.1)             18 (41.9)   

^a^Pearson Chi-squared

^b^Fishers' exact, and

^c^ANOVA one-way tests were performed for statistical analyses.

\^Phi test: Value 0.177 (Phi tests shows a positive non-significant association)

The first P-value is for the mean difference and the second one is for the prevalence difference.

The same comparison was performed between the patients with neuropathy and non-complicated in [Table 5](#pone.0237109.t005){ref-type="table"}. The examination showed that 76.2% of patients with T2DM and complicated with only neuropathy (n = 21 patients) reacted to ANCAb compared to 58.1% in non-complicated patients with no statistically significant difference (P = 0.158).

Discussion {#sec019}
==========

The present study showed that there is a difference in the number of the cases reacted to ANCAb test in the complicated patients compared to non-complicated patients, while the overall difference in reaction prevalence was not statistically significant either among multi-complication, mono-complication, and non-complicated patients or between the T2DM patients with neuropathy and non-complicated patients. Besides, there was no substantial difference in the ANCAb concentration between complicated and non-complicated patients in either category.

The presence of ANA has been shown to associate with an autoimmune disease in a few investigations. For example, Grainger and Bethell \[[@pone.0237109.ref012]\] determined the role of the presence of high titers of antinuclear antibodies in the development of coronary atherosclerosis. They measured the serum ANA of the 40 patients aged 53--76 years old with at least 50% stenosis of three main coronary arteries and compared ANA concentration with it in 30 patients aged 48--74 years old with no evidence of coronary atherosclerosis. The ANA presented by immunofluorescent detection of human antibodies bound to HEp-2000 cells was detected at least in 1/40 in 28 (70%) of the cases, but only five (17%) of the controls (OR: 11.67; 95% CI: 3.91--17.82; P\<0.001). The cases with severe coronary atherosclerosis had higher titers of ANA compared to those patients with normal coronary arteries. The similar findings were reported in T2DM and T1DM patients affected with peripheral neuropathy. Janahi, Santos \[[@pone.0237109.ref011]\] included 30 patients with DPN, 30 diabetic control patients without neuropathy, and 20 healthy control in a case-control study. The investigators found the significant positive reaction of ANA in the serum of the DPN compared to the control groups with the odds 50 times higher of positive values of ANA in the neuropathy group compared to the control groups. Besides, a significant correlation was found between the presence of ANA and the neurological manifestation of neuropathy. The neurological manifestations were neuropathy symptom score, neuropathy disability score, and vibration perception threshold.

We examined this kind of association with different complications in a quantitative technique in patients with T2DM; however, we did not find the significant difference in the prevalence of positive ANCAb between patients in the complicated and non-complicated groups despite the prevalence of reaction was high in our cases (71.1%). It is important to mention that Janahi, Santos \[[@pone.0237109.ref011]\] included both T1DM and T2DM in DPN and diabetic groups. Importantly, the etiology of these two types of diabetes are different since T1DM is an autoimmune disease. Even there is an early appearance of anti- GAD65-- specific T-cells in T1DM, and it has a strong role in the onset of the T1DM disease \[[@pone.0237109.ref007]\]. It has been reported that T1DM patients with high GAD65 antibodies have a positive correlation with neurological defects \[[@pone.0237109.ref008]\].

Zinman, Kahn \[[@pone.0237109.ref028]\] found a similar β-cell function between GAD-positive and -negative patients. However, GAD positive patients had higher HDL cholesterol and lower triglyceride levels. Hathout, Thomas \[[@pone.0237109.ref029]\] reported 8.1% of positive ICAs, 30.3% of positive GADs, and 34.8% of positive IAAs in a pediatric population with T2DM. We refer the high titers of reaction to ANCAb in cases and control in this investigation (71.1% and 58.1%, respectively) to latent autoimmune diabetes in adults (LADA) \[[@pone.0237109.ref030]\]. It claims that autoimmunity is the key responsible factor of LADA, because diabetes has biochemical markers of β-cells directed autoimmunity \[[@pone.0237109.ref030]\]. Moreover, LADA is related to a "mild" form of T1DM. However, it is not clear, whether the ANA detected in the neuropathy sample relates to DM itself or antibodies related to neuropathy.

It is interesting to mention that most of the currently available investigations have performed the antinuclear antibodies in a qualitative way. Therefore, patients with little inflammation have responded positively to the test. Even the patients with LADA could have a positive reaction to the autoimmunity test. The findings of Grainger and Bethell \[[@pone.0237109.ref012]\] in their second step, which was conducted in a semi-quantitative method approve our results.

As Grainger and Bethell \[[@pone.0237109.ref012]\] mentioned, this association might infer either a correlative association or a causative association in either direction. Also, the implication of a pro-inflammatory phenotype in the development of vascular diseases might lead to some mis-regulation of inflammatory responses and independently results in increased development of atherosclerosis and increased incidence of ANA positivity or vice versa. Repeated myocardial necrosis, even on a little scale, could be adequate to result in leakage of intracellular antigens and induces ANA production. They hypothesized that the presence of ANA might potentiate the development of atherosclerosis through helping the local inflammatory response at the site of lipid deposition into the vascular wall where cellular necrosis occurs.

We found that non-complicated group has significantly higher value in waist circumference and a trend to higher BMI compared to complicated group. This finding confirms the role of adipose tissues (AT) in systemic and B cell intrinsic inflammation, decreased B cell responses and autoimmune antibodies' secretion. The adipocytes in the human obese subcutaneous AT (SAT) enable to secrete several pro-inflammatory cytokines and chemokines that are responsible to the establishment and maintenance of local systemic inflammation. Obesity is responsible for decreased oxygen and consequent hypoxia and cell death result in further secretion of pro-inflammatory cytokines, "self-protein antigens, cell-free DNA and lipids \[[@pone.0237109.ref031]--[@pone.0237109.ref033]\].

The currently available review study explained the assumption of the pathogenesis of T2DM that encompasses autoimmune aspects and it is recognized increasingly based on the presence of circulating autoantibodies against β cells, self-reactive T cells, and on the glucose-lowering efficacy of some immunomodulatory therapies in T2DM. The LADA in elderly patients with the slowly progressive manifestation of diabetes resulted in a combination of T2DM and T1DM features. Although the autoantibody cluster of the patients with LADA and T1DM are different, the presence of these indicators reflects steady progression toward β-cell death and subsequent requirement for initiation of insulin treatment in a shorter period compared to autoantibody-negative T2DM patients. The autoimmune activation in T2DM appears to be contributed to the chronic inflammatory status. Cryptic 'self' antigens induce an autoimmune response in the case of inflammation-induced tissue destruction that accelerates β-cell destruction \[[@pone.0237109.ref013]\]. We recommend further quantitative investigations on the comparison of ANA/ANCAb between the T2DM with and without microvascular complications.

Strengths and limitations {#sec020}
-------------------------

This is the sole study that determined the ANCAb reaction in a quantitative technique. We applied restricted inclusion and matching criteria to include the patients in both complicated and non-complicated groups. However, the findings reported in this study must be interpreted with caution since the quantitative technique was used to measure the ANCAb in contrast with the literature. It is hard to make a between-study comparison due to using different titers to measure ANA since the patients with high titers (≥1:640) are more susceptible to autoimmune disease compared to the patients with low ANA titers (≤1:640) \[[@pone.0237109.ref034]\]. It was hard for the investigators to include a large sample size in this study owing to financial restriction and patients' availability and we did not include the healthy control group. In addition, we did not verified the results with another measurement technique owing to financial resources. Besides, we did not perform the ocular tests for all patients. The patients who had vision complain during physical and clinical investigations were referred to an ophthalmologist only.

Conclusions {#sec021}
===========

This study found that the concentration and reaction of the ANCAb to autoimmune antibodies was not statistically different between the T2DM patients with and without complications, either in uni-complication or multi-complications, or types of microvascular complications. In addition, the ANCAb concentration was not statistically different in patients with controlled or uncontrolled T2DM. The authors suggest to examine the same autoimmune antibody in one type of microvascular complication and with a larger sample.

Supporting information {#sec022}
======================
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Deldar Morad et al. describe the prevalence and concentration of human anti-nucleolus autoantibodies (ANCAb) in a small cohort of individuals with diabetes mellitus type 2 (T2DM), respectively in subjects with microvascular complications (n=38) and without complications (n=43).

Though the topic is interesting per se, there are several severe systematic and design problems.

\- Why did the authors choose anti-nucleolus autoantibodies (ANCAb) as their target biomarker? What would be other autoimmune reactions in this group of individuals with T2DM? Picking one autoantibody is not enough to characterize a potential autoimmune component.

\- Though the duration of T2DM is described to be similar, the definition of microvascular complications is very vague and several sub-entities are mixed-up in this group.

\- There is no clear procedure, how the individuals "without complications" have been examined. Ocular tests only in patients with self-reported complaints is far from being the right screening method in this disease. Therefore, the assignment in the one or the other group might be misleading and explaining the lack of differences.

\- Performing one assay of one company in these circumstances is not a suitable approach. Technical problems might have lead to a number of zero values, as shown in Figure 1 -- there is no description on assay performance and sensitivity/specificity, neither on false positive or false negative rate.

\- The duration of T2DM in both groups (9.0 vs. 5.0 years; P=0.065) is very diverse, as seen in the p value -- with 4 years from diagnosis and a potential longer undiagnosed duration before, these groups are not comparable

\- As male and female individuals have very different risk factors for vascular diseases and autoimmunity, they should not be mixed up in groups. The more in the small groups in this study.

\- The conclusions are not supported by the data and analyses.

Reviewer \#2: In this study the authors want to further elucidate the role of autoimmunity in Type 2 diabetes. To do that they investigated whether there are qualitative and quantitative differences in the levels of Human Anti Nucleolus Antibody (ANCAb) in sera of Type 2 diabetes patients with and without diabetes-related complications. The levels of ANCAb were determined by using a ELISA kit for the quantitative determination of ANCAb in serum. The authors did not find differences in reaction to ANCAb or of the amount of ANCAb in the sera of patients without diabetic complication compared to those with complications. There were also no differences in the comparison of specific complications (e.g. neuropathy) with no complications.

I think generally the results could match the criteria for publication but one major issue and some minors should be addressed before:

1\) Methods:

The main question for me arises in regard to the performed ELISA and the results obtained by it. In the methods section the authors nicely report the patient selection and clinical evaluation. However the description of the Human Anti Nucleolus Antibody measurement is not sufficient in my point of view:

Please provide detailed protocol of how you performed the assay. Most of the results the authors report are in regard to "reaction to ANCAb". I can't find any description of what is actually meant by that or how that measurement was performed, or which cut-offs were used ("In the current study, any reaction of ANCAb with components of the body\'s healthy cells is was considered a reacted ANCAb.").

Can you give any references of other studies which used that assay? How are the results when a healthy control group is tested in regard to "any reaction of ANCAb with components of the body healthy cells".

Minor:

Introduction:

\- In their introduction the authors briefly highlight some findings in regard to autoimmunity in diabetes type 1 and 2 and at the end focus on the possible role of anti-nuclear antibodies. Maybe you can provide any thoughts or rationale on why to test the specific subset of Anti Nucleolus Antibody.

\- The authors state: "Although different studies suggested that antibodies may be present in the sera of T2DM patients with complications \[...\]"

Please specify.

\- Please check the abbreviations. If an abbreviation is introduced it should be used from there on consistently (e.g. T2DM, ANCAb ...)

Methods:

\- Section "Diagnosis and Measurement Criteria" : Provide units for HbA1c.

\- Section" Human Anti Nucleolus Antibody measurement":

"Serum ANCAb was performed \[...\]" � Sentence doesn't make sense, please reframe.

"In the current study, any reaction of ANCAb with components of the body\'s healthy cells is was considered a reacted ANCAb" � Check again ("is was")

Results:

\- At the end of the manuscript you provide Figure 1 A-D. However the figure is not mentioned in the text at all. Please also provide detailed figure legends.

\- In table 5 you provide the number of patients affected by several complications or combinations of complications. However some are missing e.g. the number of patients suffering from CVD-complication is not given and you didn't test for differences between CVD-complications and without complications. Is there a reason why some of the complications have been left out or have not been tested?

\- Paragraph 5 of the result section: "To have a better picture of the reaction to ANCAb in patients with different types of complications, the prevalence of ANCAb reaction in different categories of complications was presented in Table 4".

� Table 4 shows the comparison between controlled and uncontrolled diabetes not the different categories of complications

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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• A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.
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Response: The manuscript was send to SCREBENDI Language services. The certificate and its tracked changes was attached as well.
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• A clean copy of the edited manuscript (uploaded as the new \*manuscript\* file)
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3\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.
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Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.
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Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

Response: There is no restriction to share the data to the public. Just it would be applicable after acceptance.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4\. Thank you for stating the following in the Acknowledgments Section of your manuscript:

\'The study was funded by the authors only.\'

Comment:

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Response: The study was not funded by any organization. The statement was removed from the manuscript.

Comment:

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\'None\'

5\. Thank you for stating the following in your Competing Interests section:

\'None\'

Response: I removed the funding statement from the manuscript.

Comment:

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state \"The authors have declared that no competing interests exist.\", as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>

Response: I filled the form.

Comment:

This information should be included in your cover letter; we will change the online submission form on your behalf.

Response: This information was added to the cover letter. Please see it in the attached file.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Comment:

6\. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure.

Response: The figures were referenced to the text in the results. Please see the manuscript.

Comment:

7\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Additional Editor Comments (if provided):

Response: We have not any supporting file for this manuscript.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

Comment:

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

Response: We tried to make a connection between the results and conclusions. Please see the manuscript.

Comment:

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: I Don\'t Know

Response: I checked the statistical extractions of the manuscript. Please see it.

Comment:

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

Response: We uploaded the SPSS file for the review process if required.

Comment:

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Response: Thanks.

Comment:

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Deldar Morad et al. describe the prevalence and concentration of human anti-nucleolus autoantibodies (ANCAb) in a small cohort of individuals with diabetes mellitus type 2 (T2DM), respectively in subjects with microvascular complications (n=38) and without complications (n=43).

Though the topic is interesting per se, there are several severe systematic and design problems.

Comment:

\- Why did the authors choose anti-nucleolus autoantibodies (ANCAb) as their target biomarker?

Response: The role of Anti-nuclear antibodies (ANA) has been investigated in few studies with controversial findings. We hypothesized that the autoimmunity could be developed within an anti-nucleolus rather than nuclear level. Therefore, we measured anti-nucleolus autoantibodies (ANCAb) between the patients with and without micro-complications in T2DM patients.

Comment:

What would be other autoimmune reactions in this group of individuals with T2DM? Picking one autoantibody is not enough to characterize a potential autoimmune component.

Response: It is right, but we had not sufficient financial resources to include other autoantibodies in the study.

Comment:

\- Though the duration of T2DM is described to be similar, the definition of microvascular complications is very vague and several sub-entities are mixed-up in this group.

Response: The primary endpoint was the first record of one of the following 12 cardiovascular presentations in any of the

data sources: stable angina, unstable angina, myocardial infarction, unheralded coronary death, heart failure, transient ischaemic attack, ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage, peripheral arterial disease, abdominal aortic aneurysm, and a composite outcome consisted of cardioversion, ventricular arrhythmia, implantable cardioverter defibrillator, cardiac arrest, or sudden cardiac death (Reference: Shah, A.D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C.P., Deanfield, J., Smeeth, L., Timmis, A. and Hemingway, H., 2015. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1· 9 million people. The lancet Diabetes & endocrinology, 3(2), pp.105-113.

Comment:

\- There is no clear procedure, how the individuals "without complications" have been examined.

Response: The patients who attended the out-patient clinic for medical check-up or receiving their regular medications were screened physically and clinically by the study internist. The study internist has weekly regular clinical duty in the out-patient clinic. The patients were screened for the possible complications of T2DM and consisted microvascular diseases, neuropathy, nephropathy, and retinopathy. The patients who were diagnosed to have one of the mentioned above complications following diabetes were categorized as T2DM patients with complication. The T2DM patients who did not have the complications were categorized as T2DM patients without complications. Please see the manuscript.

Comment:

Ocular tests only in patients with self-reported complaints is far from being the right screening method in this disease. Therefore, the assignment in the one or the other group might be misleading and explaining the lack of differences.

Response: We did not refer all patients to an ophthalmologist. We felt that it is not necessary to refer all patients to the ophthalmologist. Therefore, only patients who had a complaint on their visions during investigation were referred to the eye clinic.

Comment:

\- Performing one assay of one company in these circumstances is not a suitable approach.

Response: We had limited financial resources to purchase the material assays of another company as well, since the study was not funded by any organization.

Comment:

Technical problems might have led to a number of zero values, as shown in Figure 1 -- there is no description on assay performance and sensitivity/specificity, neither on false positive or false negative rate.

Response: We added the required information. Please see the manuscript.

Comment:

\- The duration of T2DM in both groups (9.0 vs. 5.0 years; P=0.065) is very diverse, as seen in the p value -- with 4 years from diagnosis and a potential longer undiagnosed duration before, these groups are not comparable

Response: I checked the diverse of the disease duration in a dot plot. They are not diverse. They have just some outliers in both groups. But, the outliers are not extreme. Please see the following graph.

Comment:

\- As male and female individuals have very different risk factors for vascular diseases and autoimmunity, they should not be mixed up in groups. The more in the small groups in this study.

Response: Both groups have more females than males with the statistically comparable way (P=0.244). We did the comparison of ANCAb between males and females in Table 3. However, we could not include only males or females, because we could not obtain the target number of complicated patients within the planned time period. In that case, we needed longer time period to include the target number of patients into the study.

Comment:

\- The conclusions are not supported by the data and analyses.

Response: I did revision in the conclusions. Please see the manuscript.

Reviewer \#2: In this study the authors want to further elucidate the role of autoimmunity in Type 2 diabetes. To do that they investigated whether there are qualitative and quantitative differences in the levels of Human Anti Nucleolus Antibody (ANCAb) in sera of Type 2 diabetes patients with and without diabetes-related complications. The levels of ANCAb were determined by using a ELISA kit for the quantitative determination of ANCAb in serum. The authors did not find differences in reaction to ANCAb or of the amount of ANCAb in the sera of patients without diabetic complication compared to those with complications. There were also no differences in the comparison of specific complications (e.g. neuropathy) with no complications.

I think generally the results could match the criteria for publication but one major issue and some minors should be addressed before:

Comment:

1\) Methods:

The main question for me arises in regard to the performed ELISA and the results obtained by it. In the methods section the authors nicely report the patient selection and clinical evaluation. However the description of the Human Anti Nucleolus Antibody measurement is not sufficient in my point of view:

Please provide detailed protocol of how you performed the assay. Most of the results the authors report are in regard to "reaction to ANCAb". I can't find any description of what is actually meant by that or how that measurement was performed, or which cut-offs were used ("In the current study, any reaction of ANCAb with components of the body\'s healthy cells is was considered a reacted ANCAb.").

Response: The required information was added to the methods section. Please see the manuscript.

Comment:

Can you give any references of other studies which used that assay? How are the results when a healthy control group is tested in regard to "any reaction of ANCAb with components of the body healthy cells".

Response: With respect to the ANCAb, this is the first study that used ANCAb for the T2DM patients. However, about ANA, there are few studies; for example the following:

Grainger, D.J. and Bethell, H.W.L., 2002. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Annals of the rheumatic diseases, 61(2), pp.110-114.

Janahi, N.M., Santos, D., Blyth, C., Bakhiet, M. and Ellis, M., 2015. Diabetic peripheral neuropathy, is it an autoimmune disease?. Immunology letters, 168(1), pp.73-79.

Comment:

Minor:

Introduction:

\- In their introduction the authors briefly highlight some findings in regard to autoimmunity in diabetes type 1 and 2 and at the end focus on the possible role of anti-nuclear antibodies. Maybe you can provide any thoughts or rationale on why to test the specific subset of Anti Nucleolus Antibody.

Response: We found few investigation that examined the role of antinuclear antibodies (ANA) in development of complications in T2DM patients. We hypothesized that development of complications in T2DM patients may be searched in an anti- nucleolus level rather than nuclear one. Therefore, we decided to work on the anti- nucleolus layer rather than nuclear one.

Comment:

\- The authors state: "Although different studies suggested that antibodies may be present in the sera of T2DM patients with complications \[...\]"

Please specify.

Response: We specified the studies. Please see the manuscript.

Comment:

\- Please check the abbreviations. If an abbreviation is introduced it should be used from there on consistently (e.g. T2DM, ANCAb ...)

Response: I checked and revised as appropriate.

Comment:

Methods:

\- Section "Diagnosis and Measurement Criteria" : Provide units for HbA1c.

Response: It was provided. Please see the manuscript.

Comment:

\- Section" Human Anti Nucleolus Antibody measurement":

"Serum ANCAb was performed \[...\]" � Sentence doesn't make sense, please reframe.

"In the current study, any reaction of ANCAb with components of the body\'s healthy cells is was considered a reacted ANCAb" � Check again ("is was")

Response: They were revised as appropriate. Please see the manuscript.

Comment:

Results:

\- At the end of the manuscript you provide Figure 1 A-D. However the figure is not mentioned in the text at all. Please also provide detailed figure legends.

Response: That is right, I did the reference to the text. Please see the manuscript.

Comment:

\- In table 5 you provide the number of patients affected by several complications or combinations of complications. However some are missing e.g. the number of patients suffering from CVD-complication is not given and you didn't test for differences between CVD-complications and without complications. Is there a reason why some of the complications have been left out or have not been tested?

Response: We had not sufficient number of patients with CVD in both group to make a comparison.

Comment:

\- Paragraph 5 of the result section: "To have a better picture of the reaction to ANCAb in patients with different types of complications, the prevalence of ANCAb reaction in different categories of complications was presented in Table 4".

� Table 4 shows the comparison between controlled and uncontrolled diabetes not the different categories of complications

Response: It was changed to the Table 5. Please see the manuscript.
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Dear Dr. Abdulah,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please address all points of Reviewer 2.

Please submit your revised manuscript by Aug 01 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Andreas Zirlik, MD

Academic Editor
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Some of the issues have been addressed, but several important points, like the ocular tests in ALL patients (which is mandatory for every DM subject and would only support the statistical outcome in terms of microvascular complications) seem to be not available.

In addition, the assay data are not convincing and not supportive for the author\'s conclusions.

Priority for publication is therefore low.

Reviewer \#2: In my opinion, the revised versionn of the manuscript provided by the authors has improved in quality but there are still some issues that need to be addressed:

1\) Can you give any references of other studies which used that assay? How are the results when a healthy control group is tested in regard to "any reaction of ANCAb with components of the body healthy cells".

Response: With respect to the ANCAb, this is the first study that used ANCAb for the T2DM patients. However, about ANA, there are few studies; for example the following: Grainger, D.J. and Bethell, H.W.L., 2002. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Annals of the rheumatic diseases, 61(2), pp.110-114.

Janahi, N.M., Santos, D., Blyth, C., Bakhiet, M. and Ellis, M., 2015. Diabetic peripheral neuropathy, is it an autoimmune disease?. Immunology letters, 168(1), pp.73-79.

Comment: I understand this is the first study which tested for ANCAb in T2DM patients. My question was if there are data on ANCAb reaction in healthy controls. In their discussion the authors attribute the reported reactions to ANCAb to latent autoimmune diabetes in adults. I don\'t think this conclusion is valid if there is no comparison to a group of matched healthy controls. I would suggest to include a control group of matched healthy controls to see if there is a role of ANCAb reaction in T2DM patients at all.

2\) One of the differences of the two groups was waist circumference with higher values in the non-complicated group (107.95 to 102.30). Also there was a trend to higher BMI in the non-complicated group. Since adipose tissue is known to to contribute to secretion of autoimmune antibodies that potentially could disguise an estimated higher amount of ANCAb reaction in more complicated disease. Maybe the authors could add that in their discussion.

3\) I think many of the points reviewer 1 mentioned are valid (like verification by another method or looking for different autoantibodies) and if they can not be resolved they should at least be discussed or added in the limitation section.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr. Abdulah,

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

Kind regards,

Andreas Zirlik, MD

Academic Editor

PLOS ONE

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Comment: Reviewer \#1: Some of the issues have been addressed, but several important points, like the ocular tests in ALL patients (which is mandatory for every DM subject and would only support the statistical outcome in terms of microvascular complications) seem to be not available.

In addition, the assay data are not convincing and not supportive for the author\'s conclusions.

Priority for publication is therefore low.

Response: As we mentioned previously, we did not perform the ocular tests for all patients. The patients were physically and clinically screened by the study internist for any possible complications. The patients who had vision complaints were referred to an ophthalmologist only. We honestly report that the ocular tests were not performed for all patients. We added into the limitations of the study as well.

Reviewer \#2: In my opinion, the revised version of the manuscript provided by the authors has improved in quality but there are still some issues that need to be addressed:

Comment: 1) Can you give any references of other studies which used that assay? How are the results when a healthy control group is tested in regard to "any reaction of ANCAb with components of the body healthy cells".

Response: We did not find other references that used this test. But, the following is the link of the test company with required information. We attached the catalogue of the company for this test into the application.

The link of the test of the company:

<https://www.mybiosource.com/human-elisa-kits/anti-nucleolus-antibody-ana/7228076>

Also, we found this test from another company as well. The following is the link of this test for the Human anti-nucleolus antibody and Mouse anti-nucleolus antibody test, respectively.

<https://www.biocompare.com/9956-Assay-Kit/2796027-Human-anti-nucleolus-antibody-ANA-ELISA-Kit/?pda=9956>\|2796027_0\_0\|\|11\|ANA

<https://www.biocompare.com/25138-Assay-Kit/13280700-Mouse-anti-nucleolus-antibody-ANA-ELISA-Kit/?pda=9956>\|13280700_0\_0\|\|27\|ANA

Concerning healthy controls, it was good to include the healthy controls in the study. However, we had financial restrictions for this study. Therefore, we added as a limitation into the study.

Comment:

Response: With respect to the ANCAb, this is the first study that used ANCAb for the T2DM patients. However, about ANA, there are few studies; for example the following: Grainger, D.J. and Bethell, H.W.L., 2002. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Annals of the rheumatic diseases, 61(2), pp.110-114.

Janahi, N.M., Santos, D., Blyth, C., Bakhiet, M. and Ellis, M., 2015. Diabetic peripheral neuropathy, is it an autoimmune disease?. Immunology letters, 168(1), pp.73-79.

Comment: I understand this is the first study which tested for ANCAb in T2DM patients. My question was if there are data on ANCAb reaction in healthy controls. In their discussion the authors attribute the reported reactions to ANCAb to latent autoimmune diabetes in adults. I don\'t think this conclusion is valid if there is no comparison to a group of matched healthy controls. I would suggest to include a control group of matched healthy controls to see if there is a role of ANCAb reaction in T2DM patients at all.

Response: We could not include the healthy controls in this study due to financial resources. If we included the healthy controls, the sample size would be reduced more than this. We added this point to the study limitations as well. Please see the manuscript.

Comment: 2) One of the differences of the two groups was waist circumference with higher values in the non-complicated group (107.95 to 102.30). Also there was a trend to higher BMI in the non-complicated group. Since adipose tissue is known to contribute to secretion of autoimmune antibodies that potentially could disguise an estimated higher amount of ANCAb reaction in more complicated disease. Maybe the authors could add that in their discussion.

Response: We added the relevant information about this point. Please see the manuscript.

Comment:

3\) I think many of the points reviewer 1 mentioned are valid (like verification by another method or looking for different autoantibodies) and if they cannot be resolved they should at least be discussed or added in the limitation section.

Response: We added this point to the limitation. Please see the manuscript.

Comment:

7\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.
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If you choose "no", your identity will remain anonymous but your review may still be made public.
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We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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Dear Dr. Abdulah:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.
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